<DOC>
	<DOCNO>NCT01134120</DOCNO>
	<brief_summary>The purpose study find safe dose range study drug patient myeloproliferative disorder .</brief_summary>
	<brief_title>A Study Myeloproliferative Disorders</brief_title>
	<detailed_description>The purpose study learn : 1 . How much often LY2784544 give patient 2 . What safety profile LY2784544 side effect might associate 3 . How LY2784544 take , distribute , break , pass body 4 . Whether LY2784544 help patient myeloproliferative disorder 5 . If marker blood ( biomarkers ) identify patient respond good study drug . The planned duration study fix . The length time patient participate study determine investigator/study doctor . Part A study determine dose study drug . Part A divided two section , A1 A2 . In Part A1 , patient give study drug without lead-in period . In Parts A2 B , patient lead-in period 2 4 week low dose LY2784544 prior take high dose LY2784544 . Part B study confirm safety dose schedule .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Have diagnosis polycythemia vera ( PV ) , essential thrombocythemia ( ET ) , myelofibrosis ( MF ) define World Health Organization ( WHO ) diagnostic criterion myeloproliferative neoplasms meet follow additional subtype specific criterion : A. PV : fail intolerant standard therapy refuse take standard medication B . ET : fail intolerant standard therapy refuse take standard medication C. MF ( patient MF must meet least one follow ) : i. intermediate highrisk MF accord Lille scoring system ; ii . symptomatic MF spleen great 10 cm leave costal margin ; iii . postpolycythemic MF ; iv . postET MF Have quantifiable JAK2 V617F mutation Have discontinue previous approved therapy myeloproliferative disorder , include chemotherapy , immunomodulating therapy ( example , thalidomide , interferonalpha ) , immunosuppressive therapy ( example , corticosteroid great 10 mg/day prednisone equivalent ) , radiotherapy , erythropoietin , thrombopoietin , granulocyte colony stimulate factor least 14 day recover acute effect therapy . Hydroxyurea use control blood cell count permit study entry subject maintain stable dose least 4 week . Lowdose acetylsalicylic acid ( aspirin ) permit well Have receive treatment within 14 day initial dose study drug experimental agent receive regulatory approval indication Are currently treat agent metabolize CYP3A4 narrow therapeutic margin ( example , alfentanil , cyclosporine , diergotamine , ergotamine , fentanyl , pimozide , quinidine , sirolimus , tacrolimus ) CYP2B6 ( example , cyclophosphamide , ifosfamide , tamoxifen , efavirenz , propofol , methadone , bupropion ) Are currently treat warfarin one derivatives know alter level protein C protein S. An exception criterion allow patient prior history BuddChiari Syndrome treat warfarin one derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>